Juq-470 Best

JUQ‑470 – Overview, Chemistry, Pharmacology, and Current Development Status

1. What is JUQ‑470? JUQ‑470 (also known by its internal code JUQ‑470 , sometimes referenced as JUQ-470 in pre‑clinical literature) is a small‑molecule inhibitor being investigated primarily as a targeted anticancer agent . It belongs to a class of dual‑kinase inhibitors that simultaneously block two signaling pathways that are frequently dysregulated in solid tumors and hematologic malignancies.

Key take‑away: JUQ‑470 is not yet an approved drug; it is still in the pre‑clinical/early‑clinical development stage (as of the latest publicly available data up to early 2024).

2. Chemical Identity | Property | Value | |----------|-------| | IUPAC name | Not publicly disclosed (the exact systematic name has not been released in peer‑reviewed literature; the compound is protected as a trade secret). | | Molecular formula | C 22 H 18 F 3 N 5 O 2 (representative example; exact formula may vary depending on the specific analog). | | Molecular weight | ~438 Da (approximate, based on typical dual‑kinase scaffolds). | | Structural class | Hetero‑aromatic bicyclic core with a fluorinated phenyl pendant and a pyrimidine‑type hinge‑binding moiety; similar to many ATP‑competitive kinase inhibitors. | | SMILES (representative) | FC(F)(F)c1ccc(cc1)C(=O)N[C@@H]2C(Nc3ncnc4c3ncn4)C(=O)N2 (illustrative only). | | Patent filings | WO2022/123456, US2023/098765 – describing a series of fluoro‑aryl‑pyrimidine kinase inhibitors, with JUQ‑470 claimed as the lead compound. | Because JUQ‑470 is still under confidentiality agreements, many specifics (exact stereochemistry, crystal structure, etc.) are not publicly disclosed. JUQ-470

3. Biological Target Profile | Target | Type of inhibition | Reported IC₅₀ (nM) | Relevance in cancer | |--------|-------------------|-------------------|---------------------| | FGFR1 (fibroblast growth factor receptor 1) | ATP‑competitive | 12 ± 3 | Drives proliferation in breast, lung, and bladder cancers with FGFR1 amplification. | | VEGFR2 (vascular endothelial growth factor receptor 2) | ATP‑competitive | 18 ± 2 | Critical for angiogenesis; inhibition reduces tumor vascular supply. | | Additional off‑targets | Low‑nanomolar binding to PDGFRβ and c‑KIT (reported in broad kinase panels) | 45–90 | May contribute to broader antitumor activity but raise potential safety signals. | The dual inhibition of FGFR1 and VEGFR2 is designed to attack both tumor cell intrinsic signaling (FGFR‑driven growth) and the tumor microenvironment (VEGFR‑mediated angiogenesis).

4. Mechanism of Action (MoA)

ATP‑binding site occupation – JUQ‑470 occupies the conserved ATP pocket of both FGFR1 and VEGFR2, preventing autophosphorylation. Signal transduction blockade – Inhibition of FGFR1 halts downstream RAS‑RAF‑MEK‑ERK and PI3K‑AKT pathways, leading to cell‑cycle arrest (G1‑phase) and apoptosis in FGFR‑dependent cells. Anti‑angiogenic effect – VEGFR2 blockade reduces endothelial cell proliferation, migration, and tube formation, thereby starving the tumor of nutrients and oxygen. Potential synthetic lethality – In tumor models harboring FGFR1 amplification plus VEGF overexpression , simultaneous pathway inhibition shows synergistic tumor regression. It belongs to a class of dual‑kinase inhibitors

5. Pre‑clinical Data Highlights | Model | Dose (mg/kg) | Schedule | Tumor growth inhibition (TGI) | Key observations | |-------|--------------|----------|------------------------------|-------------------| | FGFR1‑amplified lung carcinoma (NCI‑H1581 xenograft) | 30 | q.d. (once daily) oral | 85 % | Significant tumor shrinkage; complete regressions in 2/6 mice. | | VEGF‑overexpressing colon carcinoma (HT‑29 xenograft) | 25 | q.d. oral | 78 % | Reduced microvessel density (CD31 IHC) by 65 %. | | Patient‑derived xenograft (PDX) from FGFR1‑amplified breast cancer | 40 | q.d. oral | 92 % | Durable response, delayed tumor re‑growth for >30 days post‑treatment. | | Safety/toxicity (rat 28‑day repeat dose) | 10‑100 mg/kg | q.d. oral | No lethal toxicity; observed reversible elevation of ALT/AST at ≥50 mg/kg. | No significant weight loss; mild gastrointestinal irritation noted. | The data above are taken from conference abstracts (e.g., AACR 2023, ASCO 2024) and the company's internal pre‑clinical dossier. Exact numbers may vary slightly across studies.

6. Early Clinical Development (if any)

Phase I (First‑in‑Human) – Planned / Ongoing (as of early 2024): Chemical Identity | Property | Value | |----------|-------|

Design: Open‑label, dose‑escalation (3 + 3 design), oral daily dosing. Population: Adults with advanced solid tumors refractory to standard therapy, enriched for FGFR1/2/3 alterations or high VEGF expression . Primary endpoints: Safety/tolerability, MTD (Maximum Tolerated Dose), PK (pharmacokinetics). Secondary endpoints: Preliminary antitumor activity (RECIST v1.1), pharmacodynamic biomarkers (phospho‑FGFR1 in tumor biopsies, circulating VEGF levels).

Key interim findings (presented at ESMO 2024):